Engene Holdings Inc.’s protocol amendment to its phase II trial with detalimogene voraplasmid in bladder cancer worked out in ...

The U.K. government has published a road map for phasing out animal testing in life sciences research and announced £75 ...

Researchers from Chemdiv Inc. and Eilean Therapeutics LLC recently presented preclinical data on ZE77-0273, an AI-designed, ...

At first glance, the results of the CLOSURE-AF study would seem to spell doom for left atrial appendage closure devices for patients at risk of stroke, but there is some noise in the signal, including ...

In a deal worth $1.2 billion, Suzhou Sanegene Bio Inc. and Eli Lilly and Co. are partnering to advance RNAi candidates for metabolic diseases based on Sanegene's tissue selective delivery technology.

Biopharma happenings in Asia-Pacific including deals and partnerships, grants, preclinical data and other news in brief: Cue Biopharma, Immunoscape, Lakeshore Biopharma, Oceanpine Skyline, Oceanpine ...

CDR-Life Inc. has presented data on the preclinical characterization of CDR-111, a CD19/BCMA dual T-cell engager for treating ...

Synchron Inc.'s recent $2 million raise for its Stentrode brain-computer interface platform comes at a pivotal time for the ...

The Schlafen (SLFN) family of interferon-inducible genes, involved in the regulation of immune and antiviral responses, has ...

Pfizer Inc. emerged over the weekend as the winner of the bidding war for Metsera Inc., with the two reaching an amended ...

Kestra Medical Inc. seems to have put itself in a position to take a bite out of the market for wearable defibrillators with ...

Cogent Biosciences Inc. is now lining up two NDA submissions for its tyrosine kinase inhibitor bezuclastinib in treating two ...